Repository logo
  • English
  • Español
  • Log In
    Have you forgotten your password?
Universidad Tecnológica Indoamérica
Repository logo
  • Communities & Collections
  • Research Outputs
  • Projects
  • Researchers
  • Statistics
  • Investigación Indoamérica
  • English
  • Español
  • Log In
    Have you forgotten your password?
  1. Home
  2. CRIS
  3. Publications
  4. Single vs. Dual Agonist Pharmacotherapy for Managing Insufficient Weight Loss and Weight Regain Following Metabolic and Bariatric Surgery: A Comparative Review
 
Options

Single vs. Dual Agonist Pharmacotherapy for Managing Insufficient Weight Loss and Weight Regain Following Metabolic and Bariatric Surgery: A Comparative Review

Journal
Nutrients
ISSN
2072-6643
Date Issued
2026
Author(s)
Reytor González, Claudia
Facultad de Ciencias de la Salud y Bienestar Humano
Martín Campuzano-Donoso
Gerardo Sarno
Martha Montalvan
Raquel Horowitz
Gianluca Rossetti
Vincenzo Pilone
Luigi Barrea
Giovanna Muscogiuri
Luigi Schiavo
Simancas Racines, Daniel
Facultad de Ciencias de la Salud y Bienestar Humano
Type
journal-article
DOI
10.3390/nu18040553
URL
https://cris.indoamerica.edu.ec/handle/123456789/10010
Abstract
Weight management after metabolic and bariatric surgery remains a persistent clinical challenge, particularly when patients experience insufficient weight loss or progressive weight regain following the postoperative nadir. In recent years, pharmacological therapies targeting gut-derived hormones have reshaped the therapeutic approach, offering nonsurgical strategies that directly influence appetite regulation, satiety, and energy balance. Single agonists acting on the glucagon-like peptide one receptor have demonstrated meaningful reductions in body weight among postoperative patients, while dual agonists that target both the glucagon-like peptide one receptor and the glucose-dependent insulinotropic polypeptide receptor have shown even greater weight reduction in early studies, suggesting enhanced therapeutic potential. These benefits, however, must be interpreted within the unique anatomical, nutritional, and behavioral context of individuals who have undergone metabolic and bariatric procedures, as they are inherently at higher risk for micronutrient deficiencies, gastrointestinal intolerance, and maladaptive eating patterns. Successful treatment requires a balanced integration of pharmacotherapy, individualized nutritional guidance, psychological support, and a patient-centered model of long-term care. Although emerging evidence is promising, dedicated clinical trials are still needed to directly compare the efficacy, safety, and sustainability of single versus dual agonist therapies in postoperative populations. Furthermore, culturally sensitive dietary strategies and shared decision-making processes are essential to enhance adherence, optimize long-term outcomes, and ensure equitable access to treatment. Ultimately, these therapies represent a significant advance in addressing postoperative weight challenges, but their full potential will rely on comprehensive, multidisciplinary frameworks that support both biological and behavioral aspects of chronic weight management.
Subjects
  • bariatric surgery

  • glucagon-like peptide...

  • glucose-dependent ins...

  • pharmacotherapy

  • weight gain

  • weight loss

Views
1
Acquisition Date
Apr 6, 2026
View Details
google-scholar
Downloads
Logo Universidad Tecnológica Indoamérica Hosting and Support by Logo Scimago

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science

  • Cookie settings
  • Privacy policy
  • End User Agreement
  • Send Feedback